Mirae Asset Global ETFs Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.84M	Buy	31,377 +773	+3%	+$80.7K	﹤0.01%	965
2026 Q1	$3.21M	Sell	30,604 -185	-0.6%	-$16.4K	﹤0.01%	980
2025 Q4	$2.69M	Sell	30,789 -82	-0.3%	-$6.71K	﹤0.01%	1020
2025 Q3	$2.05M	Sell	30,871 -4,970	-14%	-$282K	﹤0.01%	1141
2025 Q2	$1.98M	Sell	35,841 -1,562	-4%	-$75K	﹤0.01%	1108
2025 Q1	$1.81M	Buy	37,403 +348	+0.9%	+$14.6K	﹤0.01%	1198
2024 Q4	$1.43M	Buy	37,055 +1,550	+4%	+$67.6K	﹤0.01%	1349
2024 Q3	$1.6M	Buy	35,505 +3,385	+11%	+$137K	﹤0.01%	1268
2024 Q2	$1.11M	Buy	+32,120	New	+$941K	﹤0.01%	1403

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's PTGX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Protagonist Therapeutics (PTGX) stake by 2.5% in Q2 2026, buying an estimated $80.7K and bringing the position to 31,377 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Mirae Asset Global ETFs Holdings first reported a position in PTGX in Q2 2024 and has held it in 9 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 31,377 shares of Protagonist Therapeutics worth $3.84M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 773 Protagonist Therapeutics shares in Q2 2026, an estimated $80.7K.
Protagonist Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #965 holding.
Mirae Asset Global ETFs Holdings first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 9 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.